Skip to main content

Advertisement

Table 1 Main demographic, clinical and functional data of the group of severe asthmatics

From: Comorbidities are associated with different features of severe asthma

  N 72
Age, years (nean ± sd) 59.1 ± 11.1
Gender, M/F (%) 34.7/65.3
Smoke, Y/Ex/N (%) 5.5/33.3/61.2
Atopy (%) 47 (65.2)
Duration of disease, yrs (median and range) 20.6 (2–57)
Age of asthma onset, yrs (median and range) 40 (2–68)
Early onset asthma, n (%) 10 (13.8)
Post-bronc FEV1, % of pred (mean ± SD) 86.6 ± 17.8
FeNO, ppb (median and range) 22.4 (3.5–86.5)
Sputum eosinophils, % (median and range) 18 (0–95.6)
Sputum neutrophils, % (median and range) 29 (0–96.9)
Blood eosinophils, cells/µl (median and range) 285 (0–2490)
Blood Eosinophils, % (median and range) 4.5 (0–30)
Total IgE, IU/mL (median and range) 275.9 (8.1–3830)
ACT (median and range) 19 (7–25)
ACQ (median and range) 1.65 (0–3.7)
AQLQ (median and range) 4.7 (2.7–6.9)
PEF variability (median and range) 18.6 (3.7–47)
GINA, not controlled, n (%) 37 (51.4)
Exacerbations, no./last year (median and range) 1 (0–15)
  1. FEV1 forced expiratory volume in the first second, PD20FEV1 provocative methacholine dose of a 20% drop in FEV1, FeNO fractional exhaled nitric oxide, ACT asthma control test, ACQ asthma control questionnaire, AQLQ asthma quality of life questionnaire